We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure coreplatform@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Immune dysfunction is an important feature of multiple myeloma and infection remains a major cause of morbidity and mortality. Numerous defects of the immune system occur in multiple myeloma and can also be observed in monoclonal gammopathy of uncertain significance. Indeed, evidence suggests that immune deficiency and infection may serve to promote progression to MM.
There has also been considerable interest in the identification of an autologous response against myeloma. Although cellular and humoral responses directed against myeloma-associated antigens have been described, it remains somewhat uncertain if the immune system plays a significant role in preventing or controlling myeloma cell growth. Despite this, there is an increasing interest in the potential role of immunotherapeutic approaches to treatment paraproteinemia although the immunologically hostile environment associated with multiple myeloma remains a major challenge.
An improved understanding of the mechanisms that mediate immune surveillance and tumor immunity in myeloma are important as a basis for improving patient outcome and are the subject of this review (Table 7.1).
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.